1. Peptide-based eye drops prove promising for retinitis pigmentosa
Researchers believe peptide-based eye drops could be a simple, safe and effective way to slow vision loss in patients with retinitis pigmentosa (RP).
Two RP mouse models were used to test chemically synthesised peptides with an affinity for the pigment epithelium-derived factor (PEDF) receptor, PEDF-R. The peptides were delivered as eye drops. Another vector was engineered to enable intravitreal delivery (inside the eye) of mice. Retinal organoids were also used to better assess peptide effects in human tissue. These were exposed to cigarette smoke extract to create oxidative stress.
The researchers concluded that peptide-based eye drops offer a promising, minimally invasive therapy to prevent photoreceptor degeneration in retinal disorders. The pre-clinical study was published in Communications Medicine.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The College of Optometrists and The Association of Optometrists (AOP) warn the current self-declaration system puts more lives at risk of death or injury.
The College of Optometrists' public consultation on the next edition of its Guidance for Professional Practice is open for feedback until Monday 3 August 2026.